Advertisement
Advertisement
FATE
Fate Therapeutics, Inc.
1.88
USDSponsored
-0.21
-10.29%
Nov 05, 15:23 UTC -5
Open
Fate Therapeutics, Inc. (FATE) Earnings
FATE Earnings Reports
Positive Surprise Ratio
FATE beat 25 of 43 last estimates.
58%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.14M
/-$0.29
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
-16.70%
/+7.41%
Fate Therapeutics, Inc. earnings per share and revenue
On Oct 29, 2026, FATE reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.27 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.16 million, with a --% difference.
Looking ahead to Q4 26, 12 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 1.14 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Certara, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.09
Surprise
-0.88%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
Lexicon Pharmaceuticals, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.03
Surprise
+49.41%
REGENXBIO Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.31
Actual
-$0.62
Surprise
+52.77%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
Cognition Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.04
Surprise
+41.18%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.05
Surprise
+42.59%
Disc Medicine, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.76
Actual
-$1.53
Surprise
+13.11%
Palvella Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.82
Actual
-$1.70
Surprise
+7.05%
FAQ
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Fate Therapeutics, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Fate Therapeutics, Inc.'s Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 12
analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.29 and revenue of $1.14M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.